Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935025 | 0.81 | AKT1 (0.50) | AKT1AKT2 | |
| SCHEMBL2933352 | 0.72 | AKT1 (0.45) | AKT1AKT2 | |
| SCHEMBL13368336 | 0.69 | ALDH1A1 (0.63) | — | |
| SCHEMBL13341898 | 0.69 | NPC1 (0.54) | — | |
| SCHEMBL8286546 | 0.68 | TSPO (0.48) | — | |
| SCHEMBL13368337 | 0.68 | KDM4E (0.64) | — | |
| SCHEMBL12503380 | 0.66 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL8286551 | 0.66 | TSPO (0.48) | — | |
| SCHEMBL5566700 | 0.65 | ALDH1A1 (0.65) | — | |
| SCHEMBL2932378 | 0.64 | GABRA1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-7148353-B2 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1682549-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | Sepracor Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005044818-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044818-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | AKT1 3142/4885AKT2 3198/4885 |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | CNR1, CNR2, GABRA5 | AKT1 3142/4885AKT2 3198/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | AKT1 3409/4885AKT2 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.